SCHEMBL21708320

SCHEMBL21708320

CCCCCCN(CCCCCC)C(=O)c1ccc(O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 7/20 0.57
EGFR P00533 3/20 0.55
ERBB2 P04626 2/20 0.55
CNR2 P34972 1/20 0.53
GAA P10253 1/20 0.53
HPGD P15428 1/20 0.53
ESR1 P03372 3/20 0.50
ADRA2A P08913 2/20 0.50
ADORA3 P0DMS8 2/20 0.50
TACR2 P21452 2/20 0.50
SLC6A2 P23975 2/20 0.50
SLC6A4 P31645 2/20 0.50
SLC6A3 Q01959 2/20 0.50
LMNA P02545 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
SHBG P04278 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
HSPD1 P10809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26015713 0.93 HPGD (0.61) HSD17B3EGFRERBB2CNR2GAA
SCHEMBL5968307 0.93 EGFR (0.62) HSD17B3EGFRERBB2GAAHPGD
SCHEMBL10759435 0.93 EGFR (0.61) EGFRERBB2CNR2GAAHPGD
SCHEMBL10725111 0.93 EGFR (0.61) EGFRERBB2CNR2GAAHPGD
SCHEMBL10758915 0.93 EGFR (0.61) EGFRERBB2CNR2GAAHPGD
SCHEMBL9645501 0.91 EGFR (0.63) EGFRERBB2CNR2GAAHPGD
SCHEMBL27899698 0.86 EGFR (0.55) EGFRERBB2CNR2GAAHPGD
SCHEMBL10767369 0.86 RARB (0.57) EGFRERBB2CNR2GAAHPGD
SCHEMBL10762716 0.86 RARB (0.57) EGFRERBB2CNR2GAAHPGD
SCHEMBL10761149 0.86 RARB (0.57) EGFRERBB2CNR2GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3611175-B1 NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF YAMAMOTO CHEMICALS INC (JP) 2022-02-09 EP disclosed
US-11174274-B2 Naphthalocyanine compound, method for producing same, and use thereof YAMAMOTO CHEMICALS, INC. (JP) 2021-11-16 US disclosed
US-20210107924-A1 NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF YAMAMOTO CHEMICALS, INC. (JP) 2021-04-15 US disclosed
EP-3611175-A1 NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF Yamamoto Chemicals, Inc. (JP) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107924-A1 NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF MRPS9, INTS9, RPL19 HSD17B3 1801/4885EGFR 953/4885ERBB2 2959/4885
US-11174274-B2 Naphthalocyanine compound, method for producing same, and use thereof MRPS9, INTS9, RPL19 HSD17B3 1801/4885EGFR 953/4885ERBB2 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.